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Abstract
Background: Cytotoxic T cells detect intracellular pathogens by surveying peptide loaded MHC class I molecules (pMHC I)
on the cell surface. Effective immune surveillance also requires infected cells to present pMHC I promptly before viral
progeny can escape. Rapid pMHC I presentation apparently occurs because infected cells can synthesize and present
peptides from antigenic precursors called defective ribosomal products (DRiPs). The molecular characteristics of DRiPs are
not known.
Methodology/Principal Findings: Here, using a novel method for detecting antigenic precursors and proteolytic
intermediates, we tracked the synthesis and processing of Epstein-Barr Virus encoded nuclear antigen 1 (EBNA1). We find
that ribosomes initiated translation appropriately, but rapidly produced DRiPs representing ,120 amino acid truncated
EBNA1 polypeptides by premature termination. Moreover, specific sequences in EBNA1 mRNA strongly inhibited the
generation of truncated DRiPs and pMHC I presentation.
Significance: Our results reveal the first characterization of virus DRiPs as truncated translation products. Furthermore,
production of EBNA1-derived DRiPs is down-regulated in cells, possibly limiting the antigenicity of EBNA1.
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Introduction
The MHC class I molecules present peptides (pMHC I) on the
cell surface as potential targets for recognition by the CD8+ T cell
repertoire. The expression of new pMHC I in cells infected with
microbial pathogens or in transformed cells allows the antigen
receptors of CD8+ T cells to identify those cells as foreign and to
eventually cause their elimination [1,2,3]. The effectiveness of
immune surveillance however, depends upon the ability of cells to
rapidly generate appropriate pMHC I. Timing is particularly
important during virus infections to ensure that infected cells are
detected before viral progeny are released. The antigen processing
pathway for generating pMHC I is therefore required to be
comprehensive as well as expeditious.
The MHC I antigen processing pathway does not distinguish self-
from non-self proteins: virtually all proteins are used to generate a
vast array of pMHC I on the cell surface [1]. Initially, intracellular
polypeptides are fragmented by the proteasome in the cytoplasm
[4,5]. The mixture of proteolytic intermediates is actively transported
into the endoplasmic reticulum (ER) [6,7]. In the ER, the antigenic
fragments are further trimmed and loaded onto the MHC I mole-
cules which chaperone the peptides to the cell surface [8,9,10]. While
evidence for the later steps is compelling, the initial entry of poly-
peptides into the antigen processing pathway is not well understood.
Cells contain thousands of different proteins, in distinct
intracellular compartments and at varying levels of abundance.
Among all these possible sources, newly synthesized polypeptides
are used more efficiently as antigenic precursors [11,12], in
comparison to polypeptides undergoing normal turn-over [13].
Several independent studies have provided evidence linking
protein synthesis with pMHC I presentation [14,15,16]. The
preference of ‘‘new’’ over ‘‘old’’ could allow the antigen processing
pathway to rapidly sample a wide array of endogenous proteins
soon after their synthesis for presentation as pMHC I. This
selection criterion nevertheless poses a conundrum. Most newly
synthesized polypeptides are destined for folding and normal
biological functions. Yet, a fraction of translated polypeptides
enter the mutually exclusive antigen processing pathway for
fragmentation into peptides for presentation as pMHC I.
The newly synthesized polypeptides which serve as substrates
for antigen processing have been termed DRiPs for defective
ribosomal products [17]. DRiPs could be marked for proteasomal
degradation because they contain inevitable errors in translational
or post-translational processes for producing normal functional
proteins. Alternatively, it has been hypothesized that a novel set of
‘‘immunoribosomes’’ may specialize in producing DRiPs as
unique substrates for antigen processing [18]. While attractive
from the vantage of immune surveillance, the nature of DRiPs
remains unknown. Furthermore, it has been difficult to distinguish
which cohort of newly synthesized polypeptides serve as precursors
for antigen processing versus those with normal biological
functions [18,19].
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used for immune surveillance, analysis of DRiPs might be possible
during synthesis of viral proteins. The Epstein-Barr Virus (EBV) is
a gammaherpesvirus well known for its ability to establish life-long
latency [20]. Despite EBV’s quiescence, infected cells express the
EBNA1 protein to maintain the viral episome. EBNA1 is therefore
a hallmark of EBV latency and EBV associated cancers as well as a
potential source of pMHC I [21]. Notably, EBV evades immune
surveillance because peptides derived from wild-type EBNA1 are
presented poorly by MHC I on the cell surface due to presence of
a stretch of glycine-alanine codons (GAr) [22,23,24,25]. The GAr
could affect pMHC I presentation by inhibiting proteolytic activity
of the proteasome [26,27]. Alternatively, because it inhibits
translation of EBNA1, GAr could also affect generation of DRiPs
used for antigen presentation [28,29,30]. These hypotheses remain
unresolved because the putative DRiPs produced during EBNA1
translation have not yet been identified.
DRiPs as evanescent substrates for antigen processing are
difficult to detect using conventional methods. We recently
described a novel strategy to detect otherwise invisible antigenic
precursors and proteolytic intermediates in the antigen process-
ing pathway [6,7,31]. The proteolytic intermediates, containing
antigenic peptides with N-and C-terminal flanking residues, are
normally inactive in conventional T cell assays. However, by
enzymatically releasing the T cell activating peptide from inactive
polypeptides, the antigenic precursors can be readily analyzed
in cells.
Here we analyzed the translation and processing of the EBNA1
protein associated with EBV latency. We found that ribosomes
correctly initiate EBNA1 mRNA translation in vitro but rapidly
produce truncated antigenic precursors or DRiPs. The mRNA
sequence coding for the GAr motif is responsible for the
interruption of EBNA1 translation. These DRiPs are rapidly
produced in cells but their amount is down-regulated compared to
antigenic precursors generated in the absence of GAr. Thus,
translation of viral mRNAs as truncated polypeptides is important
for determining the antigenicity of virus proteins.
Results
GAr inhibits protein synthesis without interfering with
translational initiation of EBNA mRNA in vitro
We used the Epstein Barr Virus (EBV) encoded EBNA1
(EBNA) protein and its derivative EBNA1DGA (DGA), without
the 705 nucleotides encoding the glycine-alanine repeat (GAr) to
define the influence of GAr on the synthesis and processing of
EBNA1 antigenic precursors in the MHC I antigen presentation
pathway. To detect expression of full-length proteins we used
cDNAs encoding the wild-type EBNA1 or the EBNA1DGA
proteins fused to the green fluorescent protein (GFP) [30]
(Fig. 1A). To follow the fate of the protein during antigen
processing, we inserted nucleotides encoding the modified
ovalbumin peptide, referred to as the ‘‘KOVAK cassette’’ in-
frame within the EBNA sequences [7]. The KOVAK cassette
Figure 1. Schematic representation of cDNA constructs encoding EBNA1 and its EBNA1DGA derivative lacking the glycine-alanine
repeat (GAr). To track the translated products, the OVA-derived epitope (SIINFEHL or SHL8) was inserted in either the N-terminal (positiona)o rC -
terminal region (positionc) of EBNA-GFP or its DGA derivative. The SHL8 antigenic peptide was flanked at its N- and C-termini by lysines (QLK- and –
KEW) to allow detection of potential antigenic intermediates containing the SHL8 peptide by enzymatic methods. The number of amino acids and
the predicted molecular weights of putative polypeptides are shown. (B) In vitro expression EBNA1 and EBNA1DGA full-length proteins. The
mRNAs encoding EBNA1 (a or c) and EBNA1DGA (a or c) were transcribed in vitro, purified and translated in a rabbit reticulocyte lysate in the
presence of radiolabeled
35S-Met or
35S-Cys as tracers. The translated products were fractionated on 7.5% SDS-PAGE gels and detected by
PhosphoImager. As controls, translation was carried out in parallel without mRNA (no mRNA) or with mRNAs encoding the 27kD KOVAK protein.
Arrows indicate the predominant products from translation of DGAa, DGAc and KOVAK mRNA (73 and 27 kD respectively). The expected location of
the 86 kD product of EBNAa and EBNAc translation is indicated by an asterisk. Autoradiographs on right show the KOVAK translated products
fractionated on higher resolution 16.5% SDS-PAGE. Data shown is representative of 3 different experiments.
doi:10.1371/journal.pone.0008692.g001
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lysine residues (K) flanking its N- and C-termini (QLK-[SHL8]-
KEW) which enable tracking the otherwise undetectable antigenic
precursors in the antigen processing pathway. These EBNA1 and
EBNA1DGA cDNA constructs are referred to as EBNAa or
DGAa when the KOVAK cassette is inserted in position a, and as
EBNAc or DGAc, when the KOVAK cassette is inserted in
position c.
We first analyzed translation of these mRNAs in an in vitro assay.
The mRNAs were used as templates for protein synthesis in a
rabbit reticulocyte lysate (RRL) with
35S-Met or
35S-Cys as
radiolabeled tracers. After 60 min., the products were fractionated
on SDS-polyacrylamide gels and analyzed by autoradiography
(Fig. 1B). Radiolabeled polypeptides were not detected without
addition of mRNA, while KOVAK mRNAs were translated into
the expected 27kD product. Likewise, high-molecular weight
bands with varying intensities were detected with EBNA1DGA
mRNAs translated with either
35S-Met or
35S-Cys tracers. The
largest of these bands corresponds to the expected 73kD full-length
DGA-GFP fusion protein (see Fig. 1A). Notably, translation of
EBNA1 mRNAs, was similar to the no mRNA control with no
detectable polypeptides with either tracer. Thus the presence of
GAr was clearly deleterious for translation of EBNA1 mRNA in
vitro [30]. Note that the negative effect of GAr was independent of
the a or c location of SHL8 within the coding sequence.
We considered the likelihood that GAr might have inhibited
synthesis of EBNA1 polypeptides by interfering with translational
initiation [28,32]. To test this possibility, we carried out primer
extension inhibition (toeprint) analysis to determine whether
ribosomes efficiently recognized the AUG initiation codon in the
EBNA mRNAs (Fig. 2). The mRNAs were added to rabbit
reticulocyte lysate (RRL) in the presence of translation elongation
inhibitors. Cycloheximide (CHX) or both CHX and sparsomycin
(SPR) prevent ribosomal movement during protein translation, but
do not interfere with ribosomal binding to the initiation codon.
The location of the mRNA bound ribosomes was determined
using reverse transcriptase (RT) to extend a
32P-labeled reverse
primer downstream of the start codon. The
32P-labeled RT
products were fractionated on urea-acrylamide gels to determine
their size in comparison to the bands obtained by sequencing the
same mRNAs. In the absence of ribosomes, the only predominant
band detected corresponded to the full-length RT product
(Fig. 2B). By contrast, in the presence of ribosomes and
elongation inhibitors, CHX alone or CHX+SPR, a strong band
Figure 2. GAr inhibits overall translation of EBNA1 mRNA without affecting ribosomal initiation. (A) Schematic of the primer extension
inhibition (toeprint) assay illustrating how presence of ribosomes bound to the mRNA initiation codon is detected by analysis of reverse transcriptase
(RT) products of varying length. (B) The mRNA encoding EBNA1 (a or c) and EBNA1DGA (a or c) were used as template for the toe-printing assay.
Reactions were carried out with either no ribosomes, or in presence of elongation inhibitors, cycloheximide (CHX), CHX plus sparsomycin (SPR),
initiation inhibitor, edeine or magnesium chelator, EDTA. Dried gels were analyzed using a PhosphoImager. The full-length and shorter RT (toeprint)
products are indicated by arrows. The toeprint corresponds to 17 nucleotides downstream of the AUG codon as judged by the size of fragments on
the sequencing gel shown on the right. (C) The intensity of the
32P radiolabeled toeprint bands observed under the indicated conditions was
quantitated and is shown as arbitrary units (AU.) Data are representative of 3 different experiments.
doi:10.1371/journal.pone.0008692.g002
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EBNA1DGA mRNAs. The size of this band, called the ‘‘toeprint’’,
corresponded to exactly 17 nucleotides downstream of the AUG
codon; reflecting the inhibition of RT caused by the leading edge
(toe) of the ribosome bound to its P site to the initiation codon in
the mRNA. As further controls, the toeprints were not detected in
the presence of translation initiation inhibitors like edeine or
bruceantin, nor when the ribosomes were disrupted by depleting
magnesium ions with EDTA (Fig. 2B). Importantly, the pattern of
the toeprint was indistinguishable between EBNA and DGA
showing that the GAr region does not influence the ribosome
initiation events (Fig. 2C). The formation of the initiation
complex was also independent of the location of the SHL8 coding
sequence within EBNA as shown by identical toeprints with
EBNAa, EBNAc, DGAa and DGAc mRNAs. Thus, ribosomes
recognized the AUG initiation codon with comparable efficiency
in both EBNA and DGA mRNAs.
Ribosomes terminate EBNA translation prematurely
Next, we addressed the possibility that despite appropriate
initiation, the ribosomes could have terminated protein synthesis
prior to reaching the authentic termination codon. Such prema-
turely terminated polypeptides would be difficult to detect as
discrete bands on SDS-PAGE gels because of their smaller size as
well as possible heterogeneity. Examination of the coding potential
of EBNA1 or EBNA1DGA mRNA showed a total of 11 Met and 40
Leu residues (Fig. 3A and Supp Fig S1). Notably, the 59 sequence
preceding the GAr contained only a single Met, encoded by the
AUG initiation codon, as well as three Leu residues two of which
were encoded by the ‘‘KOVAK’’ cassette inserted in the ‘‘a’’
position (QLK-[SHL8]-KEW, Fig. 1A). We used mRNAs for
EBNA and its DGA derivative containing the KOVAK cassette in
the ‘‘a’’ or in the ‘‘c’’ position downstream of GAr as templates
for translation in vitro (Fig. 3A). To detect putative translation
products regardless of their size or heterogeneity, we analyzed the
radiolabeled material after precipitating the polypeptides with 25%
trichloroacetic acid. As expected from the SDS-PAGE analysis,
35S-
Met was efficiently incorporated in the TCA precipitated material
translated from either DGAa or DGAc mRNAs (Fig. 3B).
However,
35S-Met incorporation in products of EBNAa or EBNAc
mRNAs was indistinguishable from the no mRNA control.
Likewise, when
3H-Leu was used as a tracer, it was incorporated
with high efficiency in polypeptides translated from either DGAa or
DGAc mRNAs (Fig. 3C). However, incorporation of
3H-Leu in
Figure 3. Ribosomes prematurely terminate translation within the 59 region of EBNA mRNA. (A) Schematic model to account for relative
differences in the translational efficiency of EBNA or DGA mRNAs. The ribosomes initiate translation at the AUG codon (59 blue dot) of either EBNA or
DGA mRNAs. However, translation is terminated within or close to the GAr region shown as [GAGA]n in the EBNA mRNA. The methionine and leucine
codons are indicated as blue or green dots respectively. The inserted SHL8 nucleotides, at either the N-terminal ‘‘a’’ or the C-terminal ‘‘c’’ positions are
shown as a red rectangle. All constructs included the indicated in-frame green fluorescent protein (GFP) sequence. (B) The mRNA coding for EBNAa,
DGAa, EBNAc or DGAc were translated in vitro in the presence of
35S-Met or
3H-Leu for 1 h. Translation products were precipitated with
trichloroacetic acid and collected by filtration. Radioactivity measured by liquid scintillation is shown as relative counts per minute compared ton o
mRNA control. Bars are average of 5 different experiments (6 standard deviation). Standard t-test was used to calculate statistically significant
differences shown as asterisks (***: p,0.001).
doi:10.1371/journal.pone.0008692.g003
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products was significantly above the no mRNA control (p,0.001).
In contrast,
3H-Leu was not incorporated above the no mRNA
background when EBNAc mRNA was translated despite efficient
recognition of its initiation codon by the ribosomes (Fig. 2). Thus,
the higher incorporation of
3H-Leu in EBNAa compared to
EBNAc correlated with the position of the KOVAK cassette
relative to the GAr. We conclude that the EBNAa mRNA was
translated into polypeptides containing Leu residues although the
overall efficiencywas clearly lower than with DGAa orDGAc. Most
importantly, changing the location of the KOVAK cassette,
including its two Leu residues, downstream of GAr abrogated
3H-
Leu incorporation. These results showed that translation of EBNA
mRNA did occur but was terminated upstream or within the
GAr region.
Truncated translation products are antigenic precursors
To directly characterize the translated polypeptides, we took
advantage of the KOVAK cassette which contains the antigenic
SHL8 peptide flanked by two lysine residues. We have shown
earlier that polypeptides containing the KOVAK cassettes can be
detected with high sensitivity [7]. This strategy is based on the fact
that even sub-femtomolar amounts of the SHL8 peptide can be
readily detected by B3Z T cells in presence of K
b-APC. However,
longer polypeptides which contain SHL8 in an internal position
remain undetectable because they are inactive in this assay. This
profound limitation in sensitivity can be overcome by enzymat-
ically releasing the exact SHL8 peptide from its embedded
location within the polypeptide sequence. The optimally active
SHL8 peptide can be released from the precursor polypeptide by
trypsin and carboxypeptidase B (CPB) due to the two lysine
residues flanking the SHL8 peptide (Fig. 4A). The polypeptides
can thus be detected by their ‘‘SHL8 activity’’ and quantitated by
comparison with a standard curve generated with synthetic SHL8
peptide (Fig. 4B).
With mRNAs encoding DGAa or EBNAa as templates in an in
vitro translation assay, SHL8 polypeptides were detected within 10
minutes after initiation of translation and reached a peak in 60
minutes (Fig. 4C). No SHL8 was detected in translation products
of luciferase mRNA, used as a negative control. Given that DGAa
is translated as a large, full-length protein (Fig. 1B), and EBNAa
translation is prematurely terminated (Fig. 3), similar ‘‘SHL8’’
activity recovered from both reactions suggests that translation of
the 59 region of these mRNAs occurred with similar efficiency.
Likewise, when the SHL8 peptide was located in the 39 ‘‘c’’
location downstream of GAr (Fig. 1), the SHL8 polypeptides were
produced from DGAc mRNA but were not detected when
EBNAc mRNA was translated. These results independently
establish that distinct regions of mRNA were translated with
different efficiencies in the presence of GAr. The translation of the
SHL8 sequence when present in the 59 ‘‘a’’ location occurred
efficiently with or without GAr. However, when SHL8 was located
in the 39 ‘‘c’’ location, the upstream GAr strongly inhibited the
translation of SHL8 containing polypeptides demonstrating
that translation was effectively terminated upstream of the SHL8
codons.
We characterized the translation products further by HPLC
fractionation. The in vitro translated polypeptides were acid
extracted, passed through a 30kD filter, and the ,30kD filtrate
was fractionated by reverse phase HPLC (Fig. 4D). Each HPLC
fraction was treated with trypsin and CPB and analyzed for
presence of SHL8 activity. As expected, no SHL8 activity was
detected in HPLC fractionated material translated from EBNAc
mRNA encoding SHL8 in the 39 region. However, when EBNAa
mRNA was translated, SHL8 polypeptides eluted in a broad peak
with .90% of total activity in fractions 7–11. In contrast, only 3%
of SHL8 polypeptides eluted in the same 7–11 fractions in
translated products of DGAa mRNA. We infer that the majority of
DGAa antigenic products (Fig. 4C) were larger than 30kD. This
inference is also in agreement with the absence of DGAc mRNA
translation products in 30kD extracts, consistent with the 59
position of SHL8.
To independently estimate their length, we pooled the ‘‘7–11’’
fractions and separated the polypeptides on tricine SDS-PAGE
gels (Fig. 4E). Six bands, ranging in size from 8–20 kD were
detected in the material after 60 minutes of EBNAa mRNA
translation. The ,12 kD band was the most prominent, followed
by the band at ,8 kD. Gel slices (S1–S4) containing these two as
well other bands were excised from the gel and tested for SHL8
activity after treating the eluted material with trypsin and CPB
(Fig. 4F). Slice S3, containing the 12 kD band had the most SHL8
activity compared to the other slices. On the other hand, SHL8
activity was not detected in slices from the no mRNA control gel.
Assuming no post-translational modifications, 12 kD corresponds
to approximately 120 residues in EBNAa (Fig. 1A). Interestingly
such polypeptides also include 19 glycine-alanine residues
consistent with termination of translation shortly after entry of
ribosomes into the GAr coding sequence. We conclude that
translation of EBNAa is terminated prematurely to produce
truncated polypeptides which fit the definition of defective
ribosomal products or DRiPs as originally proposed by Yewdell
and colleagues [17].
Truncated polypeptides are generated in living cells
To determine if similar translation products were generated in
living cells, the cDNAs were cloned in a tetracycline regulated
vector and stably transfected into the Tet-ON human embryonic
kidney cells (HEK293). Measurement of GFP fluorescence by
microscopy or flow cytometry showed that protein expression was
induced upon the addition of the tetracycline analog, doxycycline
(Supp Fig S2). In contrast to cells transfected with vector alone,
EBNAa, EBNAc, DGAa and DGAc transfected cells expressed
GFP fluorescence as early as 3 h after doxycycline addition and
reached a plateau after 24 h. Moreover, as reported earlier [30]
and similarly to our in vitro observations, GFP expression in cells
expressing full-length EBNA1 was substantially lower than in cells
expressing EBNA1DGA lacking GAr. The difference in protein
expression was not due to differential transcription, because the
cell lines contained similar amounts of mRNA measured by
quantitative RT-PCR (data not shown). Thus protein expression
was inducible in vivo and regulated by GAr in EBNA1 precursors.
To analyze processing intermediates, protein expression was
induced by treating the stable transfectants with doxycycline. The
polypeptides were acid-extracted and passed through a 30 kD
molecular weight filter and the filtrate was fractionated by HPLC.
Each fraction was then assayed for SHL8 polypeptides after
treatment with trypsin and CPB as above (Fig. 5A). In EBNAa
expressing cells, ,96% of the SHL8 polypeptides, similar to those
produced in vitro, eluted in the ‘‘7–11’’ fractions. Surprisingly,
although the ,30 kD SHL8 polypeptides were generated poorly in
vitro after translation of DGAa mRNA, the extracts of cells
expressing DGAa contained 10–40 fold higher amount of SHL8
activity in the ,30 kD material compared to cells expressing
EBNAa (Fig. 5A,B). Approximately 95% of SHL8 polypeptides
eluted in the same ‘‘7–11’’ fractions and remaining ,5% were
found in fractions 15–23. Notably, no SHL8 activity was detected
in ,3 kD filtrates or when the HPLC fractions were assayed in
PBS, trypsin or CPB alone confirming that the SHL8 containing
Monitoring Viral Gene Products
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and C-terminal residues flanking the antigenic peptide (Supp Fig
S3). In contrast, similar ,30 kD extracts of EBNAc or DGAc
expressing cells did not contain SHL8 polypeptides eluting in the
same HPLC fractions and only a small amount of activity was
detected in fractions 27–37 (Fig. 5A, lower panel). Because
HPLC elution profiles reflect the biochemical properties of the
polypeptides, we infer that the ,30kD SHL8 polypeptides
generated from the ‘‘a’’ versus ‘‘c’’ locations in the mRNA were
structurally distinct [31].
To confirm the structural features of DRiPs produced in living
cells, we analyzed the pooled ‘‘7–11’’ HPLC fractions by SDS-
PAGE as with the in vitro translation products above (Fig. 5C). In
silver stained gels, at least ten bands were detected ranging in size
from less than 10 kD to 20 kD in cells transfected with the vector
alone and in higher amounts in cells stably transfected with the
DGAa or EBNAa cDNA constructs. As in vitro translation assays,
the most prominent bands had molecular weights of approxi-
mately 12 and 8 kD but the intensity of the bands was comparable
for polypeptides extracted from EBNAa and DGAa transfected
cells. This result is consistent with the expectation that in contrast
to in vitro translation of single mRNA molecule, transfected cells
would also contain various other polypeptides which elute in the
same ‘‘7–11’’ HPLC fractions.
The material available in the gels was insufficient for mass-
spectrometric analysis. We therefore characterized the polypep-
tides contained in the bands by eluting the material from four gel
slices representing predominant as well as less prominent bands
Figure 4. Truncated translation products are antigenic precursors. (A) Schematic illustration of the KOVAK method for detection and
quantitation of proteolytic intermediates. The SHL8 (SIINFEHL) codons (red circle) are flanked at the N- and C-termini by lysine (K) residues. The
putative products of translation are collected in 10% acetic acid before HPLC fractionation. Each fraction is treated with trypsin and carboxypeptidase
B (CPB) to release the optimally active SHL8 peptide. (B) The amount of embedded SHL8 in the proteolytic intermediates (‘‘SHL8’’ activity) is shown in
two representative HPLC fractions (#9 and #18). The B3Z stimulating activity in dilutions of fraction #9 and #18 was compared with a standard
curve generated with synthetic SHL8 peptide. (C) The indicated mRNA coding for EBNAa, EBNAc, DGAa, DGAc and luciferase as a negative control,
were translated in vitro for varying time periods. Polypeptides in aliquots of the translation reactions were extracted assayed without HPLC
fractionation as in (A). (D) Products translated in 60 min. in vitro from the indicated mRNAs were passed through a 30kD molecular weight filter. The
filtrate (,30kD) was fractionated by HPLC and the amount of ‘‘SHL8’’ activity in each fraction was determined. Data shown represent 3 different
experiments. (E) Polypeptides translated from EBNAa mRNA and eluting in ‘‘7–11’’ HPLC fractions in (C) were fractionated on high resolution tricine
16.5% SDS-PAGE gels. ‘‘No mRNA’’ samples were analyzed in parallel as negative controls. The silver-stained gel shown is representative of 3 different
experiments. (F) Indicated slices (S1–S4) were excised from the gel, treated with trypsin and CPB and dilutions were tested for ‘‘SHL8’’ activity with
SHL8/K
b-specific B3Z lacZ inducible T cell hybridoma and K
b-L cells as APC. The conversion of the lacZ substrate chlorophenol b-D-pyrannoside was
measured as absorbance at 595 nm with 655 nm as reference wave length. Data are representative of 3 different experiments.
doi:10.1371/journal.pone.0008692.g004
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of SHL8 activity after trypsin and CPB treatment as well as GAr
epitopes with ELISA (Fig. 5D,E). In gel slices of vector alone
samples, neither SHL8 nor GAr activity was detected. In contrast,
SHL8 activity was detected in the ,12 kD S3 slice but not in the
other three slices from the EBNAa sample (Fig. 5D). Interestingly,
the ,12kD (S3) and the ,18kD (S4) slices from the EBNAa sample
also contained GAr epitopes as predicted by the sequence of
polypeptides with these sizes (Fig. 1A, 5E). Notably, in the DGAa
sample, three slices (S2, S3 and S4) representing ,8, ,12 and
,18kD polypeptides contained substantial SHL8 activity. However,
none of these slices contained polypeptides with GAr epitopes as
expected for the DGAa construct with deleted GAr. Taken together
these results established that cells expressing EBNAa or DGAa
constructs translate a heterogeneous mixture of DRiPs as antigenic
precursors. Further, the structure and amount of DRiPs was
determined by the presence of GAr coding sequence.
EBNA precursors are rapidly processed to the final
peptide
Finally, we determined the temporal relationship between the
generation of DRiPs and the appearance of the final processed
pMHC I. Peptides were extracted from cells expressing either full-
length EBNAa or its DGAa derivative after varying times and
fractionated by HPLC. To assay only the final processed SHL8
peptide, the fractions were assayed as such without any enzymatic
treatment (Fig. 6A). A single peak of antigenic activity, co-eluting
with the synthetic SHL8 peptide in HPLC fractions #18–20 was
detected as early as 30 minutes after inducing gene expression with
doxycycline and increased steadily over the next 24 h. We
estimated that EBNAa expressing cells produced about 0.02 and
1 fmol per million cells at 30 min and 24 h respectively. On a per
cell basis, this amount corresponds to 12 copies of SHL8 peptide
which increased to about 600 copies at 24 h. Notably, in the same
time period, the DGAa precursor yielded 5–10 fold higher amount
of processed SHL8 peptide relative to its full-length EBNAa
counterpart. Note that no SHL8 was detected in the absence K
b
indicating that SHL8 quantification corresponds to the formation
of the pMHC I (data not shown).
The EBNA1 as well as its EBNA1DGA derivatives are stable
long-lived proteins with half-lives of over 20 hours [24]. The rapid
generation of pMHC I suggested that the processed peptides were
most likely derived from newly synthesized precursors rather than
turn-over of stable EBNA1 or EBNA1DGA proteins. To test this
Figure 5. Generation of DRiPs in living cells. (A) HEK293 cells were induced to express EBNA or DGA with SHL8 in position ‘‘a’’ (upper panel) or ‘‘c’’
(lower panel) with doxycycline for 24 h. The cell extracts were passed through 30kD molecular weight filters and the ,30kD filtrates were fractionated
by HPLC. Each HPLC fraction was treated with trypsin and CPB and the amount peptides containing ‘‘SHL8’’ was determined. (B) The total amount of
‘‘SHL8’’ activity recovered in the polypeptides eluting in all HPLC fractions versus fractions ‘‘7–11’’ and ‘‘15–23’’. Data represent 3 different experiments.
(C)HEK293cellsexpressingvector alone,EBNAaorDGAa wereculturedfor24h withdoxycycline.Thecellextractswerepassedthrough30kDmolecular
weight filters and fractionated by HPLC. The polypeptides in fractions ‘‘7–11’’ were pooled and separated on tricine 16.5% SDS-PAGE. The silver-stained
gels shown is representative of three different experiments. (D) The indicated slices (S1–S4) were cut from the gel and digested for 8 h by trypsin. Each
digestedslicewassplitintotwoaliquots.Aliquotsfromtheindicatedvector,EBNAaorDGAasampleswerefurtherdigestedwithCPBfor4 h.The‘‘SHL8’’
activity was measured in the indicated dilutions using B3Z T cells and K
b-L cells as APC. The B3Z response is shown as products of the lacZ substrate
CPRG as in Fig. 4. (E) The presence of the GAr motif was detected by an ELISA assay using a mouse anti-GAr antibody and anti-mouse conjugated to
horse-radish peroxidase. Data shows the absorbance (A450) of the peroxidase substrate converted in 30 min.
doi:10.1371/journal.pone.0008692.g005
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inhibitor, for three hours after inducing protein synthesis with
doxycycline. The amount of processed SHL8 peptide generated in
the cells was then estimated in cell extracts after HPLC
fractionation (Fig. 6B). In contrast to the accumulation of the
processed SHL8 peptide in untreated cells (2), cycloheximide
treatment (+) completely blocked the generation of SHL8 in
EBNAa or DGAa expressing cells. In an independent approach
that did not require inhibitors, we examined the generation of
SHL8 peptide in cells after removing doxycycline which is
required for protein expression (Supp Fig S4). The EBNAa or
DGAa expression was induced with doxycycline for 24 h and the
cells were briefly treated with mild-acid. As judged by their ability
to stimulate B3Z T cells, the acid-wash removed the pre-existing
SHL8-K
b complexes (Supp Fig S4A). To distinguish whether the
processed peptides were derived from newly synthesized or pre-
existing antigenic precursors, we measured the recovery of SHL8-
K
b complexes in the absence or presence of doxycycline (Supp
Fig S4B, C). Flow cytometry measurements showed that about
86% of EBNAa and ,99% of DGAa transfected cells were GFP+
indicating that these antigenic proteins were present in the cells
(Supp Fig S4B). Nevertheless, in the absence of doxycycline, the
Figure 6. Newly synthesized precursors are processed rapidly to the final SHL8 peptide. (A) HEK293 cells expressing K
b MHC together
with EBNAa (red) or DGAa (green) were treated with doxycycline. At the indicated time points, peptides were extracted from the cells and
fractionated by reverse phase HPLC. The fractions were assayed without any further treatment using B3Z T cells and K
b-L cells as APC and quantitated
using synthetic SHL8 as a standard (upper panel). The total SHL8 recovered at different time points is indicated in lower panel. Data are
representative of 3 different experiments. (B) Protein expression was induced in the same cells with doxycycline for 3 h. The cells were treated (+)
with the protein synthesis inhibitor cycloheximide or used as such (2). The total amount of SHL8 eluted in fractions 17 to 22 was measured at 0 h, 3 h
and 6 h. Arrow indicates addition of cycloheximide. Data shown are typical of three different experiments. (C) HEK293 cells expressing EBNAa (red) or
DGAa (green) were treated with doxycycline for the indicated times. The polypeptides were extracted and ‘‘SHL8’’ activity was quantitated as
described in Fig. 4. Total ‘‘SHL8’’ activity in fractions ‘‘7–11’’ are presented in lower panel. Data is from three different experiments. (D) Same cells
were stimulated 3 h with doxycycline following same treatments than in B. The ‘‘SHL8 activity’’ in fractions ‘‘7–11’’ was measured at 0 h, 3 h and 6 h,
in the presence or not of cycloheximide. Arrow indicates addition of drug. Data shown are typical of three different experiments.
doi:10.1371/journal.pone.0008692.g006
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SHL8 compared to cells cultured in the presence of doxycycline
(Supp Fig S4C). Thus, most of the processed SHL8 peptide was
clearly derived from newly synthesized precursors.
To establish that precursor ‘‘SHL8’’ polypeptides were
generated in the same time frame, we treated HEK293 cells
expressing EBNAa or DGAa with doxycycline for 3 h and assayed
the ‘‘SHL8 activity’’ of in cell extracts as above. The fractions
‘‘7–11’’ SHL8 polypeptides were generated within 0.5 h after
doxycycline addition in DGAa and EBNAa expressing cells
(Fig. 6C). Nevertheless, DRiPs were generated at a slower rate
and in substantially lower amounts from EBNAa containing the
GAr sequence. In both EBNAa and DGAa expressing cells, the
SHL8 polypeptides detected in fractions ‘‘7–11’’ rapidly decreased
when protein synthesis was arrested (Fig. 6D). Thus, new protein
synthesis is required for rapid production of the ‘‘7–11’’
polypeptides.
Discussion
We have shown here that cells synthesize truncated polypeptides
during translation of EBNA mRNA as potential antigenic
precursors. The appearance of these polypeptides reveals that
translation of viral mRNA yields not only the full-length protein,
but also the elusive defective ribosomal products referred to as
defective ribosomal products or DRiPs. Furthermore, because
DRiPs were produced rapidly and their expression was markedly
inhibited by the glycine-alanine repeat in EBNA, suggests that this
could be a novel mRNA translation mechanism for evading
immunity.
DRiPs were first proposed to serve as a primary source of
antigenic peptides presented by MHC I more than a decade ago
by Yewdell and colleagues [17]. The DRiPs hypothesis has since
been supported by several independent studies [11,12,15,16]. The
key advantage of using DRiPs rather than normal protein turn-
over as a source of antigenic peptides is that infected cells can use
DRiPs to present pMHC I rapidly regardless of full-length protein
turn-over. The emergence of virus derived pMHC I on the cell
surface would permit cytotoxic T cells to detect infected cells
before viral progeny are released. Although attractive from an
immunological perspective, the molecular characteristics of DRiPs
are not known and their relationship to normal protein synthesis
and turn-over is poorly understood [18,19].
Polypeptides can be defective due to errors that might occur
during or after translation. For example, ribosomes could initiate
or terminate translation at inappropriate locations in the mRNA
[33], or mis-translate codons using wrong amino acids [34]. In
addition, full-length normal polypeptides could also be considered
defective due to problems in folding or incorporation into multi-
subunit complexes [35]. Because defective polypeptides are rapidly
degraded by the proteasome they could serve as significant source
for antigenic peptides [36]. Nevertheless, such defective polypep-
tides have been difficult to analyze by conventional methods likely
due to their transience and miniscule amounts.
We used several different approaches to characterize the
antigenic precursors produced by translation of EBNA and DGAr
mRNAs (Fig. 1). As noted earlier, full-length EBNA compared to
DGA mRNA (more clear to say mRNA is translated, not protein)
was translated at a remarkably low efficiency [24,28]. Yet, the
ribosomes recognized the appropriate AUG initiation codon in
both EBNA and DGA mRNAs with similar efficiency. Thus, the
translation initiation step, a frequent target for regulating protein
synthesis [37], could not account for differences in translation of
these mRNAs. Instead, we found that the ribosomes prematurely
terminated translation of EBNA mRNA in vitro. Incorporation of
radiolabeled amino acids in the in vitro synthesized material
revealed that the majority of ribosomes translated only the 59
region of EBNA mRNA. Furthermore, analysis of EBNA
translation with the KOVAK method which allows detection of
rare antigenic precursors, revealed that the most predominant
EBNA polypeptides were heterogeneous and contained ,120
residues.
Truncated polypeptides were also produced rapidly in living
cells from both EBNAa and DGAa albeit in vastly different
amounts. The amount of DRiPs produced in cells expressing
EBNAa was less than 10% compared to DRiPs produced in cells
expressing DGAa (Fig. 5). The reason why cells produce such
different amounts of DRiPs in the presence or absence of DGAr
in living cells is not clear. Regardless, the DRiPs eluting in ‘‘7–11’’
HPLC fractions contained approximately 95% of antigenic
activity and the ‘‘15–23’’ fractions contained the remainder.
Although the identity of the small amount of polypeptides eluting
in ‘‘15–23’’ fractions is not yet known, SDS-PAGE analysis
showed that the predominant polypeptides in the ‘‘7–11’’ fractions
produced from either EBNAa or DGAa were similar; approxi-
mately 120 residues in length. Furthermore, consistent with the
presence of the unique GAr region, only the DRiPs in EBNAa
expressing cells contained the GAr epitopes. Notably, the DRiPs in
‘‘7–11’’ HPLC fractions were specific to EBNAa and DGAa
which contained the SHL8 peptide in the ‘‘a’’ location. These
polypeptides were not found in cells expressing EBNAc or the
DGAc constructs. Because HPLC elution profiles reflect the
biochemical composition of the polypeptides and are detected by
their antigenicity, it is presently unclear whether DRiPs of similar
lengths are produced from other regions of the mRNAs as well.
The production of truncated DRiPs and regulation of their
amount by GAr sequence shows that antigen presentation can be
regulated at the level of mRNA translation. The length of
truncated polypeptides places the translation termination site just
before or within the GAr region in the EBNA sequence (Fig. 1).
Interestingly, the GAr coding sequence shows a marked bias in
codon usage [38]. Although any one of four codons can be used to
specify the glycine (GGU, GGA, GGC, GGG) or the alanine
(GCU, GCA, GCC, GCG) amino acids, the GAr is encoded
almost exclusively by codons containing purines for the glycine
(GGG, GGA) and alanine (GCA) residues. In an elegant study,
Tellam and colleagues recently showed that silent substitution of
purines with pyrimidines in the GAr coding sequence enhanced
EBNA protein synthesis as well as antigen presentation[29]. Thus,
it is plausible that secondary structure of GAr mRNA impedes
ribosomal progress and explains how translation of EBNA
terminates in the vicinity of GAr sequence.
Regulating production of DRiPs at the level of mRNA
translation may serve as an immune evasion strategy for latent
viruses. Gammaherpesviruses, such as Epstein-Barr Virus (EBV)
or Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) infect
humans as persistent life-long infections [39]. Yet, expression of
EBNA1 or LANA1 latency proteins is essential for maintenance of
the EBV or KSHV viral episomes in host cells. Like EBNA1,
LANA1 also contains a ‘‘QED’’ repeat region which is implicated
in blocking presentation of pMHC I [40]. It is tempting to
speculate that episome maintenance proteins, found in herpesvi-
ruses of various species [41,42], might have evolved to inhibit
pMHC I presentation by interfering with production of DRiPs.
Knowing that DRiPs can be defined as truncated polypeptides
provides insights into structure of DRiPs and opens the door to
understanding regulation of the pMHC I repertoire in latent
viruses.
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Plasmid constructs
The pEGFP-N1 vectors containing the full-length EBNA1 or
EBNA1 without GAr (DGA) were a kind gift of R. Khanna and J.
Tellam (Queensland Institute of Medical Research, Australia)[24].
The Not I site of pEGFP-N1 was deleted by mutagenesis (59 -GTG
GCC GC) following directions provided with the QuikChange
Site-Directed Mutagenesis Kit (Stratagene). The KOVAK cassette
(QLK[SIINFEHL]KEW) was produced by PCR on overlapping
primers and cloned into Bbs I within EBNA1 (position a)o rNot I
within the FLR epitope (position c) using Rapid DNA Ligation Kit
(Roche). The primer sequences for PCR were as follows: forward
(Bbs I), (59 -CAG CAG AAG ACC AGG AGC GCA GCT GAA
GAG CAT CAT CAA CTT CGA GCA CC), reverse (Bbs I), (59 –
GGT CAG CTC CTG GTC TTC CCC ACT CCT TCA GGT
GCT CGA AGT TGA TGA TGA TG), forward (Not I), (59 -AAG
GAA AAA AGC GGC CGC CAG CTG AAG AGC ATC ATC
AAC TTC GAG CAC C), forward (Not I), (59 -TTT TCC TTT
TGC GGC CGC CCC ACT CCT TCA GGT GCT CGA AGT
TGA TGA TG). DNA fragments expressing EBNA1-GFP (a or c)
or EBNA1DGA-GFP (a or c) were obtained by PCR from
pEGFP-N1 vectors using a Hind III and Hpa I restriction sites.
They were cloned into pcDNA5/FRT/TO and pcDNA I through
the Hind III and EcoR V sites.
Cell lines
The Flp-ln T-Rex -293 cell line (Invitrogen) referred to as
‘‘HEK293’’ stably expresses the Tet repressor from pcDNA6/TR
and contains a single integrated Flp Recombination target (FRT) site
from pFRT/LacZeo. pcDNA5/FRT/TO expressing EBNA1 or
EBNA1DGA (a or c) were cotransfected with pOG44 Flp recom-
binase expression plasmid into Flp-ln T-Rex host cell according to
the manufacturer instructions. The gene of interest is integrated
in a Flp recombinase-dependent manner into the genome and
its expression induced by the doxycycline (Sigma Chemical,
500 ng/mL) to the culture medium for indicated time periods.
HEK293 clones were cultured in DMEM medium supplemented
with 10% Tet System approved fetal bovine serum (FBS) (Clontech),
25 mM Hepes-Buffer solution (Gibco-BRL), 100 IU/mL penicillin
and 100 mg/mL streptomycin (Gibco-BRL), 2 mM L-glutamine
(Gibco-BRL), 2 mM sodium pyruvate solution (Gibco-BRL), 2 mM
non-essential amino acid solution (Gibco-BRL), 0.5 mM2 - b
mercaptoethanol (Sigma Chemical) and blastacidin 10 mg/mL
(Invitrogen). After homologous recombination, clones were selected
and maintained in the presence of hygromycin B 150 mg/mL
(Invitrogen). Clones transfected by pcDNAI/neo expressing H-2K
b
were selected and maintained in medium containing G418 Sulfate
750 mg/mL (Invitrogen). The culture conditions for K
b-L fibroblasts
and SHL8/K
b-specific B3Z T hybridoma cells have been described
[7]. Analysis of RP-HPLC fractions and peptide titration were
performed in RPMI supplemented with 10% Nu-serum (BD
Biosciences). Cells were treated with epoxomycin 1 mg/mL
(Calbiochem) to inhibit proteasomes function or 50 mM cyclohex-
imide (Sigma Chemical) to inhibit translation activity. Flow
cytometry data of GFP+ cells were acquired on an XL Analyzer
(Coulter) and analyzed with FlowJo software (Tree Star). For
microscopy analysis, HEK293 were cultured 48 h on cover slides
pretreated with Poly-L-Lysine Solution 4 h at 37uC( S i g m a
Chemical) and treated for indicated periods with doxycycline.
HPLC fractionation
Peptides were extracted from approximately 15610
6 cells by
boiling in 10% acetic acid solution. After centrifugation for
15 min. at 16,000 g, supernatants were filtered through Microcon
filters with a cutoff of 30 kD (Millipore). The filtrate was injected
onto a 2.16250 mm C18 reverse-phase column (Vydac) and
separated for 24 min. by a linear gradient of acetonitrile (23–35%)
with 0.1% (v/v) trifluoroacetic acid as the ion-pairing agent. Five-
drop fractions were collected in flat-bottom 96-well plates and
dried in a vacuum centrifuge. Eluted peptides were dissolved in
PBS or 20 mg/mL trypsin (Worthington) and Carboxypeptidase B
(CPB) 0.1 IU/mL (Worthington), titrated and incubated 6 h at
37uC. SHL8 activity was assayed by adding K
b-L (4610
4 per well)
and B3Z T cells (8610
4 cells per well) for 18 h in complete RPMI
medium with 10% Nu-serum (Thermo Fisher Scientific). B3Z T
cell response was assayed as previously described [43].
In vitro transcription and translation
Hpa I linearized pcDNA I plasmids were transcribed for
120 min. at 37uC as previously described [33]. Amount of purified
mRNA was measured by absorption at 260 nm. Size and integrity
of the mRNA was confirmed by electrophoresis in formaldehyde/
MOPS denaturing 1% agarose gels (Ambion). In vitro translation
was performed using the Flexi Rabbit Reticulocyte Lysate (RLL)
System (Promega) as previously described [33] with or without
35S-
Met (0.4 mCi/mL),
35S-Cys (0.3 mCi/mL) or
3H-Leu (0.5 mCi/
mL). The mRNA coding for luciferase was provided by the RLL
system (Promega). Translation reactions were fractionated on 7.5%
or 16.5% SDS-PAGE (Biorad) as indicated. Dried gels were
exposed on a PhosphoImager screen and analyzed using a Storm
PhosphoImager (Molecular Dynamics).
Trichloroacetic acid (TCA) precipitation
2 mL of the 50 mL in vitro translation reaction mixture was added
to 98 mL 1 M NaOH/2%H2O2 and incubated for 10 min. at
37uC. To this mixture, 900 mL of ice-cold 25% TCA/2%
casamino acids were added to precipitate the translation products
on ice for 30 min. The precipitate was collected by passing
through Whatman GF/C glass fiber filters wetted with cold 5%
TCA. Precipitated translation products were collected by vacuum
filtration, washed 3 times with 3 mL of ice-cold 5% TCA and
dried at room temperature. To determine
35S-Met or
3H-Leu
incorporation, radioactivity on the filters was counted in a liquid
scintillation counter (Beckmann LS600 IC). For each reaction, the
relative incorporation of radiolabel was determined as average
(cpm of ppt)/average (cpm of ‘‘no mRNA control reaction’’).
Protein bands analysis
HPLC fractions were combined with Tricine sample buffer (5%
DTT 1M, 6% glycerol, 2% SDS (w/v), 2.5% G250 1 mg/mL,
2.5% solution Tris?Cl (0.5M)/SDS (0.4% w/v), pH 6.8) and
resolved on Tris-Tricine 16.5% SDS-PAGE (Biorad) with Tris-
Tricine buffer systems. Resolving gels were either silver stained
(PlusOne Silver Staining Kit, GE Healthcare) or stained 2 h with
GelCode Blue Stain Reagent (Thermo Scientific) to analyze
protein bands. These bands were cut out and washed 20 min. in
500 mL of 100 mM NH4HCO3 and then 15 min. at 50uCi n
100 mL of 100 mM NH4HCO3 and 10 mL of 45 mM DTT. Ten
mL of 100 mM iodoacetamide was added before incubating the
solution 15 min. in the dark at room temperature. After discarding
the solvent, gel slices were washed in 500 mL of a 50:50 mix of
acetonitrile and 100 mM NH4HCO3 with shaking for 20 min. at
room temperature. After discarding the solvent, 50 mL of
acetonitrile was added to shrink the gel pieces. Solvent was
removed 15 min. later and gel fragments were dried in speed
vacuum. Gel pieces were reswelled 15 min. with 20 mL of 25 mM
NH4HCO3 containing Promega modified trypsin at 20 mg/mL.
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which were incubated 8 h at 37uC. SHL8 activity was measured
by addition of CPB as described above. For anti-GAr ELISA,
trypsin-digested gel slices solutions were titrated on MaxiSorp flat
bottom plates (Nunc) in 0.1 M carbonate buffer [0.032 M
Na2CO3, 0.068 M NaHCO3 pH 9.6] and incubated overnight
at 4uC. Coated peptides were incubated with PBS 5% milk 2 h at
37uC, washed with PBS 0.1% tween and probed 2 h at 37uC first
with anti-GAr Mab at 1 ug/mL (BioVendor Laboratory Medi-
cine, Czech Republic, clone E1-2.5) and a HRP conjugated anti-
mouse antibody (Amersham). The signal was revealed by addition
of 1-Step Ultra TMB-ELISA substrate (Pierce) 30 min. at room
temperature followed by 2 M H2SO4 (v/v). Absorbance of each
well is measured at 450 nm (reference 655 nm).
RT-qPCR
Total RNA of 10610
6 cells was isolated by using TRIZOL
Reagent (Invitrogen), treated with RQ1 RNAse-free DNase I
(Promega), purified using silica membrane spin columns (Phase
Lock Gel, Prime GmbH) and isopropanol precipitated. Four mgo f
total RNA was reverse transcribed with oligo(dT)15 primers
(Promega) using SuperScript III Reverse Transcriptase (Invitro-
gen). One fmol of purified mRNA transcribed in vitro from pcDNA
I/EBNAa and pcDNA I/DGAa was also reverse transcribed.
Their cDNA were used as a quantitative reference during RT-
qPCR. SYBR Green PCR was performed with 50 ng and 5 ng of
cDNA templates using commercial kit (Applied Biosystems) and
GeneAmp 7300 Sequence Detection System (Applied Biosystems).
Each sample was analyzed in triplicates, and the amounts of
templates were estimated by linear regression against the known
standard and normalized to internal control. The primer
sequences for the PCR were as follows: EBNA1 Forward, (59-
CTG GAA ATG GCC TAG GAG AG), EBNA1 Reverse, (59 -
CCC TCT TCT TTG AGG TCC AC), human b-Actin Forward,
(59 -GGC ACC ACA CCT TCT ACA ATG), human b-Actin
Reverse, (59-GTG GTG GTG AAG CTG TAG CC).
Primer extension ‘toeprinting’ assay of initiation
complexes
Toeprinting assay was performed as previously described [33].
The 59-end of the DNA oligonucleotide (59 -CAT CTG GAC
CAG AAG GCT C) used as the reverse primer is complementary
to the mRNA at position +64 from the AUG start codon in the
pcDNA I vector. Ribosome binding Reaction mixtures were
mixed with test compounds 2 mM edeine, 500 mg/mL cyclohex-
mide, 200 mM sparsomycin, 10 mM EDTA (Sigma)) and template
mRNA (0.5 mg/reaction). The reverse transcriptase reaction was
mixed with 3.1 pmol
32P-primer and 10 IU Avian Myeloblastosis
Virus Reverse Transcriptase (RT, Promega). Reactions were
layered onto 8% polyacrylamide sequencing gel. Dried gels were
exposed on a PhosphoImager screen and analyzed using a Storm
PhosphoImager (Molecular Dynamics).
Statistical analysis
Statistical analysisPrism software (GraphPad) was used for
statistical analyses. P values were calculated with the unpaired t-
test.
Supporting Information
Figure S1 Amino acid sequences encoded by EBNAa-GFP and
EBNAc-GFP cDNA constructs. The GAr sequence is in bold
italics and the methionine (M, blue) and leucine (L, green) residues
are indicated. Residues of the ‘‘KOVAK cassette’’ inserted in the
a or c positions are highlighted in a box.
Found at: doi:10.1371/journal.pone.0008692.s001 (0.42 MB EPS)
Figure S2 HEK293 cells were stably transfected with either
vector alone or the indicated EBNA derivatives shown in Fig 1A.
Protein expression was induced by addition of doxycycline for the
indicated time periods. Fluorescence of GFP was detected by
microscopy (A) or as mean fluorescence intensity by flow
cytometry (B). Data show mean 6 SD of triplicates and are
representative of 3 independent experiments.
Found at: doi:10.1371/journal.pone.0008692.s002 (4.41 MB EPS)
Figure S3 ‘‘SHL8’’ activity in HPLC fractionated ,30kD or
,3kD extracts from cells expressing either EBNAa or DGAa
constructs used in Fig 5. Each HPLC fraction was assayed as such
or after treatment with trypsin, carboxypeptidase B (CPB) or both
trypsin and CPB. The ‘‘SHL8’’ activity was quantitated as shown
in Fig 5. Data shown are representative of three different
experiments.
Found at: doi:10.1371/journal.pone.0008692.s003 (0.51 MB EPS)
Figure S4 pMHC I expression requires new protein synthesis.
(A) Kb+ HEK293 cells expressing EBNAa or DGAa were cultured
for 24 h in the presence of doxycycline. Cells were briefly treated
with mild-acid and used as APCs for B3Z T cells or analyzed for
(B) GFP and Kb expression by flow cytometry using PE-
conjugated anti-Kb Mab 5F1. (C) Amounts of SHL8 peptide in
cells extracted at the indicated time periods after the acid wash.
Data show mean 6 SD of duplicates and are representative of
three different experiments.
Found at: doi:10.1371/journal.pone.0008692.s004 (1.09 MB EPS)
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